Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 19

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1
Chunk 19
---
 1 issued European patent, and 1 issued Japanese patent that are solely owned by us and 4 issued U.S. patents and 5 issued foreign (Australian, Chinese, European, Japanese, and Korean) patents that we co-own with Stanford and for which Stanford has exclusively licensed its rights to us under the 2015 Stanford Agreement. In addition, as of December 31, 2025, we own or co-own with Stanford, for which Stanford has exclusively licensed its rights to us under the 2015 Stanford Agreement, approximately 202 pending patent applications in various countries (23 of which are pending in the U.S., and 7 of which are Patent Cooperation Treaty ("PCT") applications that have yet to enter the national phase in the U.S.). 

More particularly, we have 1 issued U.S. patent, 1 pending U.S. nonprovisional patent application, 1 pending PCT application that has yet to enter the national phase in one or more countries, and 24 pending foreign patent applications, which we solely own, directed to BDC-3042, our novel agonistic antibody targeting an immune-activating receptor expressed on TAMs known as Dectin-2 (CLEC6A).  The issued patent and the pending U.S. and foreign patent applications, if issued, are expected to expire between 2041 and 2044, excluding any extension of patent term that may be available.  We also have 3 pending U.S. nonprovisional patent applications, 40 pending foreign patent applications, and 2 pending U.S. provisional patent applications, which we solely own, directed to BDC-4182, our next-generation Boltbody ISAC clinical candidate targeting claudin 18.2.  The pending U.S. and foreign patent applications, if issued, are expected to expire between 2040 and 2045, excluding any extension of patent term that may be available.

In addition, we have 5 issued U.S. patents, 7 issued foreign patents, and 131 pending patent applications directed to ISAC technology other than BDC-3042 and BDC-4182, including 4 issued U.S. patents and 5 issued foreign patents covering our previous lead product candidate trastuzumab imbotolimod and the use thereof, which we co-own with Stanford and have exclusively licensed under the 2015 Stanford Agreement. Of these 131 pending patent applications, 1 is a U.S